Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European psychiatry

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eurpsy.2007.07.005PMID 17904825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.

  2008cited by this paper
• Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

  2007cited by this paper
• Atypical antipsychotics related metabolic syndrome in bipolar patients.

  2007cited by this paper
• [Prevalence of metabolic syndrome in the province of Albacete (Spain)].

  2007cited by this paper
• Prevalencia del síndrome metabólico en la provincia de Albacete

  2007cited by this paper
• Valoración y control del riesgo metabólico y cardiovascular en los pacientes con esquizofrenia

  2006cited by this paper
• Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

  2006cited by this paper
• Prevalence of the Metabolic Syndrome in Veterans with Schizophrenia

  2006cited by this paper
• High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia

  2006cited by this paper
• [Assessment and control of metabolic and cardiovascular risk in patients with schizophrenia].

  2006cited by this paper
• Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.

  2006cited by this paper
• The Mediterranean diet: is it cardioprotective?

  2005cited by this paper
• Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

  2005cited by this paper
• [Prevalence of metabolic syndrome in patients of an urban primary care centre].

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Prevalencia del síndrome metabólico en población laboral española: registro MESYAS

  2005cited by this paper
• Prevalencia del síndrome metabólico (criterios del ATP-III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia

  2005cited by this paper
• Prevalencia de síndrome metabólico en la población de un centro de atención primaria urbano

  2005cited by this paper
• Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

  2005cited by this paper
• [Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia].

  2005cited by this paper
• Dietary Influences on Blood Pressure: The Effect of the Mediterranean Diet on the Prevalence of Hypertension

  2005influential reference
• Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians.

  2005cited by this paper
• [Prevalence of metabolic syndrome in the Spanish working population: MESYAS registry].

  2005cited by this paper
• Metabolic Syndrome and Cardiovascular Disease

  2005cited by this paper
• Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia

  2004cited by this paper
• Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome

  2004influential reference
• Burden of general medical conditions among individuals with bipolar disorder.

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs.

  2004cited by this paper
• The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Metabolic Syndrome and Cardiovascular Disease

  2003cited by this paper
• C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women

  2003cited by this paper
• Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study

  2003cited by this paper
• Central adiposity determines prevalence differences of the metabolic syndrome.

  2003influential reference
• Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia

  2002cited by this paper
• Physical consequences of schizophrenia and its treatment: the metabolic syndrome.

  2002cited by this paper
• Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.

  2002cited by this paper
• The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics.

  2002cited by this paper
• The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

  2002cited by this paper
• Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities

  2001cited by this paper
• The role of stress and the hypothalamic–pituitary–adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes

  2000cited by this paper
• Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

  1999influential reference
• Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia

  1998cited by this paper
• North American Association for the Study of Obesity

  1991cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• Role of Insulin Resistance in Human Disease

  1988influential reference

• Prevalence and predictors of metabolic syndrome among psychiatric patients receiving antipsychotic treatment in Africa: a systematic review and meta-analysis

  2025influential citation
• Lipid and Glucose Profile across Different Mental Disorders

  2024influential citation
• Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs

  2022cites this paper
• Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.

  2021cites this paper
• A study on haloperidol and risperidone induced metabolic derangements in patients with newly diagnosed schizophrenia

  2020cites this paper
• Treatment-related weight gain and metabolic complications in children with mental health disorders: Potential role for lifestyle interventions.

  2020cites this paper
• Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double‐blind randomized controlled PULSAR study)

  2020cites this paper
• Prevalence and predictors of metabolic syndrome in drug naïve bipolar patients.

  2019cites this paper
• Metabolic Side Effects of Antipsychotic Medication: An Overview

  2019cites this paper
• Coronary vascular disease event risk and metabolic syndrome prevalence in patients enrolled in an assertive treatment community program.

  2018cites this paper
• Pattern of adverse reactions of antipsychotics in a tertiary care hospital

  2016cites this paper
• Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study.

  2016cites this paper
• Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis

  2016cites this paper
• Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia.

  2016cites this paper
• The metabolic syndrome in an Italian psychiatric sample: a retrospective chart review of inpatients treated with antipsychotics.

  2016cites this paper
• Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE

  2016cites this paper
• Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children.

  2015cites this paper
• Understanding of Antipsychotics in Elderly Patients with Dementia

  2015cites this paper
• Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence

  2015cites this paper
• Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder.

  2015cites this paper
• Aumento de peso y de índice de masa corporal en niños y adolescentes tratados con antipsicóticos: revisión crítica y estudio longitudinal

  2014influential citation
• Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

  2014cites this paper
• Cardiovascular risk factors among people with severe mental illness in Italy: a cross-sectional comparative study.

  2014cites this paper
• The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis

  2014influential citation
• Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia

  2014cites this paper
• Comparison of metabolic parameters and Framingham cardiovascular risk scores before and after in‐hospital treatment with antipsychotics

  2014cites this paper
• [Prevalence of metabolic syndrome in Spanish patients with schizophrenia and overweight. The CRESSOB Study].

  2014influential citation
• Syndrome métabolique chez les sujets schizophrènes: prévalence et analyse des pratiques

  2014influential citation
• Prevalencia del síndrome metabólico en pacientes españoles con esquizofrenia y sobrepeso. El estudio CRESSOB

  2014cites this paper
• Wpływ leków przeciwpsychotycznych na występowanie zespołu metabolicznego

  2014cites this paper
• Bipolar disorder and metabolic syndrome: a systematic review.

  2013cites this paper
• The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

  2013cites this paper
• A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia

  2013cites this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

  2013cites this paper
• Secondary metabolic syndrome: the frequency of factors which may underlie the parameters of metabolic syndrome

  2013cites this paper
• Metabolic syndrome in antipsychotic treated psychiatric patients.

  2013cites this paper
• Bipolar Disorder, Schizophrenia, and Metabolic Syndrome

  2013cites this paper
• Cardiovascular Disease Mortality in Chronic Schizophrenia Patients Treated with Clozapine

  2013cites this paper
• Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study

  2013cites this paper
• Bipolar disorder, schizophrenia, and metabolic syndrome.

  2013cites this paper
• The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review.

  2012influential citation
• Metabolic Syndrome in Bipolar Disorders

  2012cites this paper
• Aripiprazole in combination with lamotrigine for the long‐term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double‐blind study (CN138‐392)

  2012cites this paper
• Waist Circumference is a Sensitive Screening Tool for Assessment of Metabolic Syndrome Risk in Children Treated with Second-Generation Antipsychotics

  2012cites this paper
• Factores de riesgo cardiovascular, riesgo cardiovascular y calidad de vida en pacientes con trastorno mental severo

  2012influential citation
• New‐Onset Treatment‐Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder

  2012cites this paper
• Gender-specific lipid profiles in patients with bipolar disorder.

  2011cites this paper
• Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study

  2011cites this paper
• Primary care perspectives on treating bipolar disorder: a cross-sectional survey.

  2011cites this paper
• Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

  2010cites this paper
• Evidence-Based Practice Problems: Form and Focus

  2010cites this paper
• Bipolar disorder and metabolic syndrome: an international perspective.

  2010influential citation
• Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population.

  2010influential citation
• [Bipolar disorders and metabolic syndrome: a clinical study in 185 patients].

  2010cites this paper
• Changes in high-density lipoprotein and homeostasis model assessment of insulin resistance in medicated schizophrenic patients and healthy controls.

  2010cites this paper
• Prevalence of metabolic syndrome among patients with schizophrenia in Japan.

  2010cites this paper
• Biomarkers for Psychiatric Disorders

  2009cites this paper
• Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?

  2009cites this paper
• Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated with Second—Generation Antipsychotic Medications

  2009cites this paper
• Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications

  2009cites this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

  2009cites this paper
• Metabolic syndrome in people with schizophrenia: a review

  2009cites this paper
• Síndrome metabólico en pacientes ambulatorios con tratamiento antipsicótico en la práctica clínica habitual: evaluación transversal de una base de datos de atención primaria

  2008cites this paper
• Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.

  2008cites this paper
• Metabolomics: A Global Biochemical Approach to the Discovery of Biomarkers for Psychiatric Disorders

  2008cites this paper
• Bmc Public Health the Relationship between Effectiveness and Costs Measured by a Risk-adjusted Case-mix System: Multicentre Study of Catalonian Population Data Bases

  year unknowncites this paper